Mass drug administration for malaria

Added June 4, 2014

Read the full review here

Administration of antimalarial drugs to whole populations (mass drug administration) can reduce the initial (6 month) risk of malaria-specific outcomes, but few studies found that this effect was sustained. However, adverse events were inadequately addressed in these studies.

Malaria is the most important mosquito-borne disease caused by a parasite, accounting for an estimated 660,000 deaths annually. Fortunately, malaria is both preventable and treatable. The review aimed to assess the potential for mass drug administration to reduce malaria burden and transmission, and to identify gaps in our understanding. It highlighted that such reviews are a challenge due to the heterogeneity of the study methods employed.